Herpes simplex virus inhibitor - CytoGenix

Drug Profile

Herpes simplex virus inhibitor - CytoGenix

Alternative Names: CY-301; CYGpssXE-59; Simplivir

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CytoGenix
  • Class DNA
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Herpes simplex virus infections

Highest Development Phases

  • No development reported Herpes simplex virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (Topical, Cream)
  • 10 Jan 2008 This programme is still in active development
  • 04 Mar 2005 Preclinical data from a media release have been added to the Viral infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top